MAYZENT WAS EVALUATED
IN THE LARGEST STUDY OF
SPMS TO DATE,
WHICH INCLUDED 1651 PATIENTS WITH
FIND OUT MORE
A WIDE RANGE OF DISABILITY3,4
21 % RELATIVE RISK REDUCTION
IN 3-MONTH CONFIRMED DISABILITY PROGRESSION IN PATIENTS WITH SPMS (P=0.013)1*DISCOVER THE PROVEN EFFICACY
* Proportion of patients with 3-month CDP for MAYZENT was 26% vs 32% for patients on placebo. Although MAYZENT had a significant effect on CDP in patients with active SPMS (relapse in the 2 years prior to study entry), its effect in patients with non-active SPMS was not statistically significant.
CDP=confirmed disability progression; SPMS=secondary progressive multiple sclerosis.
References: 1. Mayzent [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; March 2019. 2. Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease. Novartis website. https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-mayzent-siponimod-first-oral-drug-treat-secondary-progressive-ms-active-disease. Published March 27, 2019. Accessed March 27, 2019. 3. Kappos L, Bar-Or A, Cree BAC, et al; for the EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018;391(10127):1263-1273. 4. New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients. Novartis website. https://www.novartis.com/news/media-releases/new-novartis-analyses-aan-show-siponimods-efficacy-disability-and-cognition-secondary-progressive-ms-patients. Published April 20, 2018. Accessed April 4, 2019.